SCHEMBL4334782

SCHEMBL4334782

Cc1cc(=O)n(CC(=O)NC(C)(C)C)[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.45
NPC1 O15118 1/20 0.45
CNR2 P34972 5/20 0.44
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
THRB P10828 1/20 0.38
MAPT P10636 2/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
POLB P06746 1/20 0.36
ENPP3 O14638 1/20 0.36
ALPL P05186 1/20 0.36
XIAP P98170 1/20 0.36
DUT P33316 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11783166 0.75 L3MBTL1 (0.44) GAALMNAL3MBTL1MAPTHTT
SCHEMBL11782694 0.70 L3MBTL1 (0.47) GAALMNAL3MBTL1MAPTHTT
SCHEMBL6850809 0.68
SCHEMBL9697614 0.67 KMT2A (0.57) GAAL3MBTL1MAPTHTTHSD17B10
SCHEMBL11783219 0.66 L3MBTL1 (0.43) GAACNR2LMNAL3MBTL1HTT
SCHEMBL13870743 0.65 L3MBTL1 (0.44) GAAL3MBTL1MAPTHTTALDH1A1
SCHEMBL11777887 0.65 L3MBTL1 (0.51) LMNAL3MBTL1MAPTHSD17B10ALDH1A1
SCHEMBL25976177 0.65 ALPI (0.48) GAANPC1CNR2LMNAMAPT
SCHEMBL19133623 0.64 CA1 (0.59) GAANPC1LMNAL3MBTL1MAPT
SCHEMBL23161263 0.64 L3MBTL1 (0.38) GAAL3MBTL1MAPTHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK GAA 2853/4885NPC1 4660/4885CNR2 4166/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK GAA 2853/4885NPC1 4660/4885CNR2 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.